147283-83-8

Basic information

• Product Name: Carbamic acid, [1,2-dihydro-2-oxo-1-[2-oxo-2-[[3,3,3-trifluoro-2-hydroxy-1-(1-methylethyl )propyl]amino]ethyl]-5-[[3-[(trifluoroacetyl)amino]phenyl]methyl]-3-pyridin yl]-, phenylmethyl ester
• CAS NO: 147283-83-8
• Molecular Formula: C30H30F6N4O6
• Molecular Weight: 656.582
• Mol File: 147283-83-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [1,2-dihydro-2-oxo-1-[2-oxo-2-[[3,3,3-trifluoro-2-hydroxy-1-(1-methylethyl )propyl]amino]ethyl]-5-[[3-[(trifluoroacetyl)amino]phenyl]methyl]-3-pyridin yl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [1,2-dihydro-2-oxo-1-[2-oxo-2-[[3,3,3-trifluoro-2-hydroxy-1-(1-methylethyl )propyl]amino]ethyl]-5-[[3-[(trifluoroacetyl)amino]phenyl]methyl]-3-pyridin yl]-, phenylmethyl ester(147283-83-8)
• EPA Substance Registry System: Carbamic acid, [1,2-dihydro-2-oxo-1-[2-oxo-2-[[3,3,3-trifluoro-2-hydroxy-1-(1-methylethyl )propyl]amino]ethyl]-5-[[3-[(trifluoroacetyl)amino]phenyl]methyl]-3-pyridin yl]-, phenylmethyl ester(147283-83-8)

Safety Data

• Hazardous Substances Data: 147283-83-8(Hazardous Substances Data)

Upstream product

• 147269-71-4 tert-butyl 3-benzyloxycarbonylamino-5-iodo-2-oxo-1,2-dihydro-1-pyridylacetate 
• 147269-68-9 3-<<(benzyloxy)carbonyl>amino>-5-iodopyrid-2-one 
• 147269-67-8 3-(benzyloxycarbonylamino)pyrid-2-one 
• 33630-99-8 3-amino-2-pyridone 
• 6332-56-5 3-nitropyridone 
• 106746-09-2 3(RS)-amino-1,1,1-trifluoro-2(RS)-hydroxy-4-methylpentane hydrochloride 
• 1025887-47-1 {3-Benzyloxycarbonylamino-2-oxo-5-[3-(2,2,2-trifluoro-acetylamino)-benzyl]-2H-pyridin-1-yl}-acetic acid 

Downstream Products

• 147268-16-4 2-[3-Benzyloxycarbonylamino-5-(3-trifluoroacetylaminobenzyl)-2-oxo-1,2-dihydro-1-pyridyl]-N-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)acetamide 

Relevant articles and documents

Non-peptidic inhibitors of human leukocyte elastase. 1. The design and synthesis of pyridone-containing inhibitors

Human leukocyte elastase (HLE) is a serine protease produced by neutrophils that has been implicated in diseases such as amphysema and cystic fibrosis. An HLE inhibitor may have therapeutic value in these diseases. An active site model of HLE bound to a t